Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease accompanied by high incidence rate of interstitial lung disease (ILD). Slit guidance ligand 3 (Slit3) which is a member of axon guidance molecule superfamily, mediates a series of biological activities. In this study, we explored the potential clinical significance of Slit3, especially as a serum biomarker for evaluating RA-ILD. Patients diagnosed with RA were recruited between July 2022 to April 2024 from the Department of Rheumatology of Foshan First People’s Hospital. The clinical data were collected from hospital records, serum level of Slit3 was detected by enzyme-linked immunosorbent assay (ELISA). Among 232 recruited patients, RA patients in high Slit3 subgroup were older, showed higher proportion of positive rheumatoid factor (RF) status and anti-cyclic citrullinated peptide antibody (APCA) status, as well as higher levels of ESR, CRP, Disease Activity Score in 28 joints with four variables, including C-reactive protein (DAS28-CRP) or erythrocyte sedimentation rate (DAS28-ESR), Simplified Disease Activity Index (SDAI) and pro-inflammatory cytokine interleukin-6 (IL-6). Notably, Logistic regression analysis showed that elevated serum Slit3 was an independent relevant factor of RA-ILD (OR 1.005 [95% CI 1.002-1.008], P=0.002). Our findings evealed that serum Slit3 was associated with disease activity in RA and may hold promise as a useful serum biomarker and therapeutic target for RA-ILD.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Ethics Committee of Foshan First People's Hospital approved this study, and all subjects signed informed consent forms before clinical data collection.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All relevant data are within the manuscript and its Supporting Information files.